A5043842591- Renal Transplantation Outcomes and Treatments
- Organ Donation and Transplantation
- Organ Transplantation Techniques and Outcomes
- Renal and Vascular Pathologies
- Dialysis and Renal Disease Management
- Nonmelanoma Skin Cancer Studies
- Cutaneous Melanoma Detection and Management
- Adolescent and Pediatric Healthcare
- Polyomavirus and related diseases
- Childhood Cancer Survivors' Quality of Life
- Cytomegalovirus and herpesvirus research
- Cutaneous lymphoproliferative disorders research
- T-cell and B-cell Immunology
- Chronic Kidney Disease and Diabetes
- Organ and Tissue Transplantation Research
- Renal Diseases and Glomerulopathies
- Pregnancy and Medication Impact
- CAR-T cell therapy research
- Biomedical Ethics and Regulation
- Healthcare Policy and Management
- Immunotherapy and Immune Responses
- HIV Research and Treatment
- Complement system in diseases
- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
Oxford University Hospitals NHS Trust
2015-2024
Churchill Hospital
2013-2024
University of Oxford
2013-2023
Science Oxford
2023
Marist College
2022
National Health Service
2020
RELX Group (United States)
2019
International Society of Nephrology
2019
Wellcome Trust
2016
European Union
2016
ABSTRACT. Acute rejection is a major cause of reduced survival renal allografts. Vascular endothelial growth factor (VEGF) mitogen for cells and expressed widely by tissue T cells. VEGF influences adhesion migration leukocytes across the endothelium. This study investigates whether genetically determined variation in expression development allograft rejection. promoter polymorphisms were examined using sequence-specific primer–PCR 173 transplant recipients. occurred 38.7%; median time to...
The European Best Practice Guideline group (EBPG) issued guidelines on the evaluation and selection of kidney donor transplant candidates, as well post-transplant recipient care, in year 2000 2002. new Renal board decided 2009 that these needed updating. In order to avoid duplication efforts with disease improving global outcomes, which published clinical practice care recipients, we did not address issues present guidelines. guideline was developed following a rigorous methodological...
<b>Problem</b> Transition from paediatric to adult care of young adults with chronic diseases is poorly coordinated, often delayed, and usually managed through a single referral letter. About 35% lose successfully functioning kidney transplant within 36 months transfer services. <b>Design</b> Before after study the impact new integrated paediatric-adult clinical service for patients failure. <b>Setting</b> Adult renal centre in Oxford two centres London. <b>Strategies change</b> An...
Abstract Objective To determine the global capacity (availability, accessibility, quality, and affordability) to deliver kidney replacement therapy (dialysis transplantation) conservative management. Design International cross sectional survey. Setting Society of Nephrology (ISN) survey 182 countries from July September 2018. Participants Key stakeholders identified by ISN’s national regional leaders. Main outcome measures Markers core components Results Responses were received 160 (87.9%)...
The global nephrology community recognizes the need for a cohesive strategy to address growing problem of end-stage kidney disease (ESKD). In March 2018, International Society Nephrology hosted summit on integrated ESKD care, including 92 individuals from around globe with diverse expertise and professional backgrounds. attendees were 41 countries, 16 participants 11 low- lower-middle-income countries. purpose was develop strategic plan improve worldwide access by identifying prioritizing...
Abstract Some people remain healthier throughout life than others but the underlying reasons are poorly understood. Here we hypothesize this advantage is attributable in part to optimal immune resilience (IR), defined as capacity preserve and/or rapidly restore functions that promote disease resistance (immunocompetence) and control inflammation infectious diseases well other causes of inflammatory stress. We gauge IR levels with two distinct peripheral blood metrics quantify balance between...
Summary Background Non‐melanoma skin cancer (NMSC) is an important complication of solid organ transplantation, especially in areas high ultraviolet light exposure. Registry data may underestimate the scale problem. Objectives A single‐observer study a Queensland renal transplant population was conducted between July 1999 and April 2000 utilizing both cross‐sectional retrospective data. The aims were to determine accurately risk NMSC following transplantation compare this with currently...
Viral-mediated oncolysis is a novel cancer therapeutic approach with the potential to be more effective and less toxic than current therapies due agents selective growth amplification in tumor cells. To date, these have been highly safe patients but generally fallen short of their expected value as monotherapies. Consequently, new approaches generating potent oncolytic viruses are needed. address this need, we developed method that term "Directed Evolution" for creating viruses.Taking...
In light of the significant morbidity and mortality cutaneous invasive squamous cell carcinomas (SCCs) in renal transplant recipients, we investigated whether conversion to sirolimus-based immunosuppression from standard could diminish recurrence rate these skin cancers.In a 2-year randomized controlled trial, 155 recipients with at least one biopsy-confirmed SCC were stratified according age (< 55 v ≥ years) number previous SCCs (one nine 10) randomly assigned sirolimus (n = 74) or...
This clinical practice guideline addresses access to kidney transplantation together with the evaluation, selection and preparation of potential transplant recipient. Guidance on medical management recipient is provided in another module Renal Association guidelines available at www.renal.org. Readers should refer joint British Society for Histocompatibility Immunogenetics/ Transplantation document detection characterisation HLA antibodies renal NHS Blood Transplant/British consent solid...
The concept of regulatory T cell (Treg)-based immunotherapy has enormous potential for facilitating tolerance in autoimmunity and transplantation. Clinical translation Treg therapy requires production processes that satisfy the rigors Good Manufacturing Practice (GMP) standards. In this regard, we report our findings on implementation a robust GMP compliant process ex vivo expansion clinical grade Tregs, demonstrating feasibility developed manufacture final product application. This...
Short-term outcomes in kidney transplantation are marred by progressive transplant failure and mortality secondary to immunosuppression toxicity. Immune modulation with autologous polyclonal regulatory T cell (Treg) therapy may facilitate reduction promoting better long-term clinical outcomes. In a Phase I trial, 12 recipients received 1–10 × 106 Treg per kg at Day +5 posttransplantation lieu of induction (Treg Therapy cohort). Nineteen patients standard (Reference Primary were...
The purpose of this Clinical Practice Guideline is to provide guidance on evaluation the kidney donor and transplant recipient as well management in perioperative period.It designed information aid decision-making.It not intended define a standard care, should neither be construed one nor it interpreted prescribing an exclusive course management. Scope target populationThis guideline describes issues related selection recipient.It encompasses aspects immunological risk assessment care does...
Regulatory T cell (Treg) therapy has been demonstrated to facilitate long-term allograft survival in preclinical models of transplantation and may permit reduction immunosuppression its associated complications the clinical setting. Phase 1 trials have shown Treg be safe feasible practice. Here we describe a protocol for TWO study, phase 2b randomised control trial living donor kidney transplant recipients that will confirm safety explore efficacy this novel treatment strategy.60 patients on...
Cutaneous squamous cell cancer (SCC) affects up to 30% of kidney transplant recipients (KTRs) within 10 years transplantation. There are no reliable clinical tests that predict those who will develop multiple skin cancers. High numbers regulatory T cells associate with poor prognosis for patients in the general population, suggesting their potential as a predictive marker cutaneous SCC KTRs. We matched KTRs (<i>n</i> = 65) and without 51) gender, age, duration immunosuppression assessed...